Gepotidacin, a novel oral inhibitor of bacterial type II topoisomerases, received approval in March 2025 for uncomplicated urinary tract infections under the brand Blujepa and is under FDA review for a separate indication in gonorrhea. The drug’s distinct binding mode against DNA gyrase and topoisomerase IV aims to overcome fluoroquinolone resistance and potentially spare gut microbiota. Regulators and clinicians are monitoring gepotidacin for both efficacy in resistant infections and safety signals that differentiate it from legacy fluoroquinolones. Ongoing review for gonorrhea could expand its use into a key public-health niche if approved.